GGrantIndex
Sort

30,917 grants matching tumor microenvironment

The Prostate Cancer Tumor Microenvironment Exhibits Differentially Expressed Gene

$781,730
Dan Mercola · University Of California-Irvine · U01 · FY2012 · CA

Reprogramming the Tumor-Immune Interface in Oral Cancer

$780,996
John B Sunwoo · Stanford University · R35 · FY2020 · DE

Mechanisms of impaired T-cell mechanosensing of melanoma antigens

$780,284
Cheng Zhu · Georgia Institute Of Technology · U01 · FY2017 · CA

Fibroblast Heterogeneity in Pancreatic Cancer

$780,205
David Tuveson · Cold Spring Harbor Laboratory · R01 · FY2023 · CA

Glutamine metabolism inhibitors for TB and TB-HIV: dual action as host-directed therapies with antibacterial activity

$780,174
William Ramses Bishai · Johns Hopkins University · R01 · FY2020 · AI

Prostate Section

$780,135
Peter Pinto · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA

Signal Transduction Events and the Regulation of Cell Growth

$780,073
Jane B Trepel · Division Of Clinical Sciences - Nci · ZIC · FY2018 · CA

Fibroblast Heterogeneity in Pancreatic Cancer

$779,963
David Tuveson · Cold Spring Harbor Laboratory · R01 · FY2022 · CA

Targeting the BCL2 immune checkpoint to enhance the immunostimulatory effects of radiation in breast cancer

$779,894
Lorenzo Galluzzi · Research Inst Of Fox Chase Can Ctr · R01 · FY2025 · CA

Human Immune Responses to Tumor Antigens for Cancer Immunotherapy

$779,653
Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA

SOAT1 as a targetable dependency in Pancreatic Adenocarcinoma

$778,873
David Tuveson · Cold Spring Harbor Laboratory · R01 · FY2025 · CA

Uncovering the Biology of Resistance to Tyrosine Kinase Inhibitors in EGFR Mutant Lung Cancer Patient-Derived Models.

$778,382
Katerina Abigail Politi · Yale University · U01 · FY2021 · CA

Enabling immunotherapy for high-risk Group 3 medulloblastoma via systems immunology

$778,050
Hongbo Chi · St. Jude Children'S Research Hospital · U01 · FY2024 · CA

Mechanisms of microenvironment mediated resistance to cancer cell surface targeted therapeutics

$777,500
David J Beebe · University Of Wisconsin-Madison · UH3 · FY2023 · CA

Mechanisms of microenvironment mediated resistance to cancer cell surface targeted therapeutics

$777,500
David J Beebe · University Of Wisconsin-Madison · UH3 · FY2022 · CA

Mechanisms of resistance to treatment in aggressive prostate cancers

$777,497
Adam Sowalsky · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

Molecular Analysis of Breast Cancer Metastasis to the Brain

$777,064
Patricia Schriver Steeg · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA

Preclinical toxicology and pharmacology evaluation of a newTNFR2 antagonistic monoclonal antibody for CTCL therapy

$776,973
Kenneth Olivier · Boston Immune Technologies And Therapeutics, Inc. · R44 · FY2024 · CA

Pancreatic Cancer Detection Consortium

$776,970
Michael A Hollingsworth · University Of Nebraska Medical Center · U01 · FY2024 · CA

Targeting the immunosuppressive tumor microenvironment to enhance efficacy of radiotherapy and immuno-radiotherapy for oral cancer

$776,961
Andrew Sikora · Baylor College Of Medicine · U01 · FY2019 · DE

Development of Drugs Acting at Adenosine Receptors

$775,838
Kenneth Alan Jacobson · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2025 · DK

Harnessing the power of exosomes for non-coding RNA delivery

$775,509
Anil K Sood · University Of Tx Md Anderson Can Ctr · R35 · FY2020 · CA

Engineering personalized micro-tumor ecosystems

$775,492
Shiladitya Sengupta · Brigham And Women'S Hospital · U01 · FY2019 · CA

Mechanisms of microenvironment mediated resistance to cancer cell surface targeted therapeutics

$775,417
David J Beebe · University Of Wisconsin-Madison · UG3 · FY2020 · CA

BCMA Specific Chimeric Antigen Receptor (CAR)-T Cells for Treatment of Patients with Multiple Myeloma

$775,192
Damian J. Green · Fred Hutchinson Cancer Research Center · P01 · FY2019 · CA